[Teplizumab (type 1 diabetes mellitus, stage 2, >= 8 years) – Addendum to Project A26-11]

Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen
Record ID 32018015959
German
Original Title: Teplizumab (Diabetes mellitus Typ 1, Stadium 2, ≥ 8 Jahre) – Addendum zum Projekt A26-11]
Details
Project Status: Completed
URL for project: https://www.iqwig.de/projekte/a26-73.html
Year Published: 2026
URL for published report: https://www.iqwig.de/download/a26-73_teplizumab_addendum-zum-projekt-a26-11_v1-0.pdf
English language abstract: There is no English language summary available
Publication Type: Full HTA
Country: Germany
DOI: https://doi.org/10.60584/A26-73
MeSH Terms
  • Diabetes Mellitus, Type 1
  • Child
  • Adolescent
  • Adult
  • Antibodies, Monoclonal, Humanized
  • Hypoglycemic Agents
Keywords
  • Teplizumab
  • Diabetes Mellitus - Type 1
  • Child
  • Adolescent
  • Adult
  • Benefit Assessment
  • NCT01030861
Contact
Organisation Name: Institute for Quality and Efficiency in Health Care (IQWiG)
Contact Address: IQWiG, Siegburger Str. 237, 50679 Cologne, GERMANY, Tel: +49(0)221-35685, Fax: +49(0)221-356851
Contact Email: berichte@iqwig.de
Copyright: Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.